Search Results

Your search matched 139 results

#1

COVID-19: How are Payers Managing These Days? | Perspectives

How are payers responding to COVID-19?

#2

Payer Priorities in a Pandemic | In The Media

What are payers focused on during the COVID-19 pandemic?

#3

Pharma & Payers - Opening the Lines of Communication | Blog

For the first time in 20 years, The FDA has issued new draft guidance on how pharmaceutical companies can communicate healthcare economic information (HCEI) with payers.

#4

Non-Personal Promotion: What Do Payers Want? | Perspectives

We talked to national and regional payers, insurers, IDNs and hospitals to get a complete picture of key challenges, unmet needs and information sources.

#5

Real World Value: Advancing Payer Understanding of RWE in Rare Disease | Perspectives

But market access challenges persist as payers in the U.S. and Europe continue to express doubts.

#6

Integrating Pharmaceutical Brand + Payer to Maximize Brand Value | Blog

As recently as five short years ago, a pharmaceutical manufacturer could develop a good product, do everything right as it pertained to the needs of both patients and healthcare professionals, and launch it successfully into the world without major worry about the product be

#7

Payers, Polls, and Pumpkin Lattes | Blog

Fall is officially here, marking week three of the NFL season (we’ve got some Browns fans in the house), the rapid approach of the midterm elections, and the kickoff of the socially acceptable window for ordering pumpkin spice lattes.

#8

November 2019: Real World Value: Advancing Payer Understanding of RWE in Rare Disease | Newsletters

But market access challenges persist as payers in the U.S. and Europe continue to express doubts.

#9

The Syneos Health Podcast, Coronavirus Special Edition: Payers and COVID-19 | Perspectives

In this Coronavirus Special Edition Series, we’ve talked a lot about the clinical implications of the COVID-19 pandemic.

#10

Digital Therapeutics at the Crossroads | Perspectives

Payer perspectives on reimbursement hurdles can help DTx companies map the journey to real-world utilization and market success.

#11

DPE15: New Digital Needs of Physicians, Payers and Patients | Blog

Monique Levy, Vice President of Research at Decision Resources Group shared a whirlwind of research and ideas about the new tensions and needs in healthcare.

#12

How payers and manufacturers can find common ground in rare diseases | Perspectives

Health insurers have raised challenging questions about how drugs for rare diseases are defined, regulated, and priced in the U.S. market.

#13

Orphan Medicines: Averting Price Debacles And Winning Payer Support | In The Media

In this collaborative piece, Meg Alexander, Managing Director of our Reputation & Risk Management practice and Susan Suponcic, Managing Director of our Pricing and Market Access practice, highlight misalignments in perception that derail access to orphan drugs.

#14

The Syneos Health Podcast: Digital Therapeutics | Perspectives

Our team discusses the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.

#15

August 2019: The Syneos Health Podcast: Digital Therapeutics | Newsletters

In this podcast our team discusses the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.

#16

Thoughts on Value-Based Arrangements from Industry Leaders | Blog

Lilly & Harvard Pilgrim Healthcare's CEOs shared their thoughts on value-based arrangements between pharma and payers

#17

Opening a New Era in Rare Disease Medicines | In The Media

Jeanine O'Kane and Marie Emms, senior executives at Syneos Health, address rare disease pricing and the ties between manufacturers, payers and patient advocacy groups.

#18

Digital Medicine and MedTech Showcase: What’s Blocking the Adoption of Digital Therapeutics? | Blog

With there being so many different stakeholders, including patients, providers and payers, panelists at the 2019 Digital Medicine & MedTech Showcase pointed to a number of different adoption roadblocks—and successes.

#19

Value & Outcomes Spotlight: Regulatory Policy and Real-World Evidence | In The Media

In this issue of "Value & Outcomes Spotlight" focused on Regulatory Policy and Real-World Evidence, Ruth Trzcienski, Compliance Director at inVentiv Health, talks about "FDA issues and their involvement with PhRMA and payers."

#20

An Overview of Co-pay Accumulator Programs | Blog

Payers are continually adjusting their management strategies in an effort to control costs.

#21

Inside the Gray Space of Digital Therapeutics | In The Media

Jennifer Kielmeyer, GSW, recaps the DTxDM conference, that brought together more than 200 senior decision-makers from digital therapeutics companies, pharma, investors, payers, and healthcare providers.

#22

Insight-Driven Communications and the Data Imperative | Perspectives

Christie Anbar, Managing Director of Chamberlain Healthcare PR, Syneos Health, participated in a recent MM&M TrendTalks roundtable focused on “spend and trends” in the areas of healthcare professional (HCP), patient and payer marketing.

#23

The Scrutiny on Rebates and Prices Will Change the Pharma-Payer Relationship | In The Media

John Seay of our Managed Markets Communications team spoke with PM360 about proposed HHS changes and the impact they will have on rebates and pricing.

#24

Two Key Questions About Payer Strategies in 2020 | In The Media

Adrian Garcia, SVP Managed Markets at GSW, a Syneos Health company, talks about price transparency and biosimilar interchangeability in this PM360 article.

#25

Trend: Rise of real world data and the new KOL | Blog

The largest payers in healthcare – including Aetna, UHC, WellPoint, and Medicare – are now compensating physicians for value in addition to volume of services.

#26

Successful Implementation of Value-Based Reimbursement Requires Partnerships Across All Healthcare Stakeholders | Blog

Investment in technology is imperative for providers who want to keep up with the changing healthcare reimbursement landscape.

#27

How Does Pharma Demonstrate Value to the Payer in the Current Environment? | Perspectives

Coverage can be the entry or roadblock to getting your product into the patient’s hands.

#28

July 2019: How Does Pharma Demonstrate Value to the Payer in the Current Environment? | Newsletters

Coverage can be the entry or roadblock to getting your product into the patient’s hands.

#29

Why Payers Lag Drug Developers and Regulators in Embracing Real-World Evidence | Perspectives

Catch Meg Alexander, Head, Reputation & Risk Management Practice at Syneos Health, on RARECast - a podcast focused on the intersection of rare disease with business, science, and policy.